Skip to search formSkip to main contentSkip to account menu

BR96-doxorubicin immunoconjugate

Known as: cBR96-doxorubicin immunoconjugate, cBR96-DOX, DOX-MOAB BR96 
An antibody-drug conjugate composed of the chimeric monoclonal antibody BR96 chemically linked to the cytotoxic drug doxorubicin. The antibody moiety… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
PURPOSE MLN2704 is an immunoconjugate designed to deliver the maytansinoid antimicrotubule agent drug maytansinoid-1 directly to… 
Highly Cited
2007
Highly Cited
2007
The prodrug bivatuzumab mertansine (BIWI 1) is a novel CD44v6-targeting humanized monoclonal antibody coupled to the toxin… 
2004
2004
Chimeric BR96-doxorubicin conjugate (BR96-DOX) is an immunoconjugate designed to specifically target and kill certain tumor cells… 
2001
2001
The chimeric monoclonal antibody cBR96 conjugated to doxorubicin (cBR96‐Dox) is selectively internalized by a wide variety of… 
Highly Cited
2000
Highly Cited
2000
OBJECTIVE To evaluate dose intensification with osmotic blood-brain barrier disruption (BBBD) and the potential use of drug… 
Highly Cited
1999
Highly Cited
1999
PURPOSE BMS-182248-1 (BR96-doxorubicin immunoconjugate) is a chimeric human/mouse monoclonal antibody linked to approximately… 
Highly Cited
1997
Highly Cited
1997
The internalizing monoclonal antibody BR96 was conjugated to the anticancer drug doxorubicin (DOX) using an acid-labile hydrazone… 
Highly Cited
1996
Highly Cited
1996
We have used a combinatorial mutagenesis strategy to humanize BR96, a monoclonal antibody that binds to the Lewis Y class of… 
1995
1995
Sodium dodecyl sulfate-capillary gel electrophoresis (SDS-CAGE), the capillary version of SDS-polyacrylamide-based slab gel… 
Highly Cited
1993
Highly Cited
1993
Immunoconjugates (BR96-DOX) were prepared between chimeric monoclonal antibody BR96 and the anticancer drug doxorubicin. The…